Neuregulin in cardiac hypertrophy in rats with aortic stenosis: Differential expression of erbB2 and erbB4 receptors

Circulation

Volumn 100, Issue 4, 1999, Pages 407-412

  Rohrbach, Susanne ^a   Yan, Xinhua ^a   Weinberg, Ellen O ^a   Hasan, Faisal ^a   Bartunek, Jozef ^a   Marchionni, Mark A ^b   Lorell, Beverly H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b CeNeS Pharmaceuticals plc   (United States)

Author keywords

Growth substances; Heart failure; Hypertrophy; Myocytes

Indexed keywords

ATRIAL NATRIURETIC FACTOR; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PROTEIN; RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AORTA STENOSIS; ARTICLE; CONTROLLED STUDY; HEART FAILURE; HEART HYPERTROPHY; HEMODYNAMICS; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; MALE; MUSCLE CELL; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033609458     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.4.407     Document Type: Article

References (43)

1. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 1991;5:3037-3046.
2. Schneider MD, Parker TG. Cardiac myocytes as a target for the action of peptide growth factors. Circulation. 1990;81:1443-1456.
3. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol phospholipid hydrolysis, sarcomeric assembly, and cardiac gene expression in ventricular myocytes. J Biol Chem. 1990;265:20555-20562.
4. Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JF, Apstein CS, Lorell BH. Distribution and functional significance of cardiac ACE in hypertrophied rat hearts. Circulation. 1993;87:1328-1339.
5. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, Lorell BH. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1994;90:1410-1422.
6. Lemke G. Neuregulins in development. Mol Cell Neurosci. 1996;7:247-262.
7. Carraway KL III, Burden SJ. Neuregulins and their receptors. Curr Opin Neurobiol. 1995;5:606-612.
8. Marchionni MA. Neu tack on neuregulin. Nature. 1995;378:334-335.
9. Burden S, Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron. 1997;18:847-855.
10. erbB2. Science. 1992;256:1205-1210.
11. Carraway KL III, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C. Neuregulin-2, a new ligand of erbB3/erbB4-receptor tyrosine kinases. Nature. 1997;387:512-516.
12. Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ. Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates erbB4. Proc Natl Acad Sci U S A. 1997;94:9562-9567.
13. Alroy I, Yarden Y. Thr erbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997;410:83-86.
14. Levi ADO, Bunge RP, Lofgren JA, Meima L, Hefti F, Nikolics K, Sliwkowski MX. The influence of heregulins on human Schwann cell proliferation. J Neurosci. 1995;15:1329-1340.
15. Marchionni MA, Kirk CJ, Isaacs IJ, Hoban CJ, Mahanthappa NK, Anton ES, Chen C, Wason F, Lawson D, Hamers FPT, Canoll PD, Reynolds R, Cannella B, Meun D, Holt WF, Matthew WD, Chen L-E, Gispen W II, Raine CS, Salzer JL, Gwynne DI. Neuregulins as potential drugs for neurological disorders. Cold Spring Harb Symp Quant Biol. 1996;61:459-472.
16. Pinkas-Kramarski R, Eilam R, Speigler O, Lavi S, Liu N, Chang D, Wen D. Schwartz M, Yarden Y. Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes. Proc Natl Acad Sci U S A. 1994;91:9387-9391.
17. Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL. GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron. 1996;17:229-243.
18. Bermingham-McDonogh O, Xu Y, Marchionni MA, Scherer SS. Neuregulin expression in PNS neurons: isoforms and regulation by target interactions. Mol Cell Neurosci. 1997;10:184-195.
19. Trachtenberg JT, Thompson WJ. Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor. Nature. 1996;379:174-177.
20. Marchionni MA, Grinspan JB, Canoll PD, Mahanthappa NK, Salzer JL, Scherer SS. Neuregulins as potential neuroprotective agents. Ann N Y Acad Sci. 1997;825:348-365.
21. Grinspan JB, Marchionni MA, Reeves M, Coulaloglou M, Scherer SS. Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. J Neurosci. 1996;16:6107-6118.
22. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA. Neuregulins (NRG) promote survival and growth of cardiac myocytes: persistence of erbB2 and erbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273:10261-10269.
23. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res. 1993;73:184-192.
24. Schunkert H, Weinberg EO, Bruckschlegel G, Riegger AJ, Lorell BH. Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding. J Clin Invest. 1995;96:2768-2774.
25. Weinberg EO, Lee MA, Weigner M, Lindpaintner K, Bishop SP, Benedict CR, Ho KKLH, Douglas PS, Chafizadeh E, Lorell BH. Angiotensin AT1 receptor inhibition: effects on hypertrophic remodeling and ACE expression in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation. 1997;95:1592-1600.
26. Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Circulation. 1995;91:2642-2654.
27. 2+ in myocytes from aortic-banded rats. Circulation. 1996;94:2915-2922.
28. + exchange is impaired in cardiac hypertrophy. J Clin Invest. 1997;99:125-135.
29. Tajima M, Weinberg EO, Bartunek J, Jin H, Yang R, Paoni NF, Lorell BH. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with post-infarction heart failure. Circulation. 1999;99:127-135.
30. Sarkar FH, Visscher DW, Crissman JD. Quantitative analysis of Her-2/neu (ERBB2) gene expression using reverse transcriptase polymerase chain reaction. Diagn Mol Pathol. 1993;2:210-218.
31. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of erbB3, a third member of the erbB/epidermal growth factor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A. 1989;86:9193-9197.
32. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M. Ligand-specific activation of HER/ p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A. 1993,90:1746-1750.
33. Gullick WJ. Type 1 growth factor receptors: current status and future work. Biochem Soc Symp. 1998;63:193-198.
34. Balselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2 antibody enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpression human breast cancer xenografts. Cancer Res. 1998;58:2825-2831.
35. O'Rourke DM, Kao GD, Singh N, Park BW, Muschel R, Wu C-J, Greene MI. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sci U S A. 1998;95:10842-10847.
36. Canella B, IIoban CJ, Gao Y-L, Garcia-Arenas R, Lawson D, Marchionni MA, Gwynne D, Raine CS. The neuregulin, GGF2, diminishes autoimmune demyelination and enhances remyelination in a model for Multiple Sclerosis. Proc Natl Acad Sci U S A. 1998;95:10100-10105.
37. Meyer D, Yamaai T, Garratt A, Riethmacher-Sonnenberg E, Kane D, Theill LE, Birchmeier C. Isoform-specific expression and function of neuregulin. Development. 1997;124:3575-3586.
38. Gassman M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the erbB4 neuregulin receptor. Nature. 1995;378:390-394.
39. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394-398.
40. Kramer R, Bucay N, Kane DJ, Martin LE, Tarpley JE, Theill LE. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc Natl Acad Sci U S A. 1996;93:4833-4838.
41. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859-870.
42. MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res. 1997;81:137-144.
43. United States Food and Drug Administration Database. Phase II trials. Herceptin-Genentech.